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Summary
Breast cancer is the most frequent female cancer in Europe and North America
and poses an important health care problem. Over the last decades extensive
l i terature has been compi led on the effect iveness of var ious diagnost ic and
treatment strategies, which has resulted in broad consensus on the most appro-
pr iate diagnost ic and treatment strategies, la id down in cl in ical  guidel ines. The
f irst  chapters of this thesis assess breast cancer treatment in the North-Nether-
lands. The main object ive of the studies presented in the chapters 1 to 5 is to
obtain insight in the loco-regional t reatment for ear ly stage breast cancer,  par-
t icular ly the surgical  t reatment,  including the axi l lary nodal staging, and adju-
vant chemotherapy. Inaddit ion, in these studies the compl iance with breast can-
cer treatment guidel ines was evaluated. The aim of the studies in the second
part  of  this thesis,  comprising the chapters 6 and 7, isto asses the r isk of second
cancers after breast cancer.  Emphasis in these studies lay on the inf luence of sys-
temic and locoregional therapy on the r isk of developing contralateral  breast
cancer and non-breast second cancers. In chapter 8 the f i rst  results of a project
aiming to ident i fy low penetrant breast cancer suscept ibi l i ty genes in the North-
Netherlands populat ion are presented.
The l i terature concerning the evaluat ion of patterns of care and measuring the
qual i ty of care was reviewed in chapter 1. The review evaluates in more detai l
what aspects may determine the treatment of elder ly breast cancer pat ients,  the
possible f fects of a mult idiscipl inary approach of breast cancer treatment and
the role of populat ion-based cancer egistr ies in the evaluat ion of breast cancer
care in the present and in the near future.
In chapter 2 we present an analysis of the var iat ion in surgical  t reatment for ear-
ly stage breast cancer and compl iance with guidel ines with respect to the appl i -
cat ion of radiotherapy and axi l lary lymph node dissect ion, before and after the
introduct ion of the sent inel  node biopsy in 13,532 stage l- l l lA breast cancer
pat ients,  diagnosed between 1989-2002. Large inter-hospital  var iat ion was
observed in performing breast conserving surgery, which persisted after adjust-
ment for case-mix. General ly,  hospitals,  which scored far under or above the
reg iona l  average,  d id  so  dur ing  the  who le  s tudy  per iod .  The gu ide l ine  adher -
ence with respect to axi l lary lymph node dissect ion and radiotherapy as part  of
breast conserving surgery was markedly lower for elder ly pat ients and breast
conserving therapy did not comply with guidel ines in 25.2o/o f  the pat ients
aged 75 years or over.  Guidel ine compl iance fel l  s ince the introduct ion of the
sentinel node biopsy procedure, from 96.1 o/o prior to 2000 to 91 .4o/o in 2002, fre-
quent ly due to omission of axi l lary lymph node dissect ion or radiotherapy
although indicated according to the guidel ines. However,  non-adherence to
guidel ines does not necessari ly ref lect poor qual i ty of care. In our populat ion,
over the years 200' l -2002,50% of the pat ients without axi l lary lymph node dis-
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sect ion,  most  of  which were o lder  than 50 years,  had a posi t ive sent inel  node
biopsy.  Radiotherapy,  as par t  of  breast  conserv ing surgery,  was more f requent ly
omit ted in  the e lder ly  pat ients,  wi th 22% of  the pat ients aged >75 years not
receiv ing radiotherapy af ter  breast  conserv ing surgery.  The benef i t  o f  ax i l lary
lymph node d issect ion for  e lder ly  pat ients has been quest ioned in the l i terature
and surgeons may be re luctant  to  per form an addi t ional  ax i l lary lymph node
dissect ion ( fo l lowing breast  conserv ing surgery or  sent inel  node b iopsy)  in  e ld-
er ly  pat ients suf fer ing f rom more ser ious co-morbid i ty .  One could argue that
the outcome of  ax i l lary lymph node d issect ion af ter  a posi t ive sent inel  node
biopsy would not  of ten change the pro jected adjuvant  t reatment  among elder-
ly  pat ients and as such may represent  appropr iate pat ient- ta i lored medical  prac-
t ice.  A recent  s tudy by the Cancer and Leukaemia Group B,  compar ing lumpec-
tomy plus tamoxi fen wi th and wi thout  radiat ion in  women wi th c l in ica l  s tage I
breast  cancer aged >70 years,  found only a smal l  excess r isk of  locoregional
recurrence in the non- i r radiated group wi thout  d i f ferences in  d is tant  metas-
tases r isk or  surv iva l  (Hughes et  a l ,  NEJM 2004;351:971-977).  Local  recurrences
rates among elder ly  pat ients who refused radiotherapy or  who had medical
contra indicat ions were found to be low for  pat ients wi th smal l ,  lower grade
tumors operated wi th adequate resect ion margins (Lee et  a l ,  Ann Surg Oncol
2004 ;11 :316 -321 ) .  A l t hough  i napp rop r i a te  acco rd ing  to  t he  gu ide l i ne ,  om i t t i ng
radiotherapy af ter  breast  conserv ing surgery in  the very e lder ly  therefore may
also be adequate medical  pract ice for  pat ients wi th smal l ,  radical ly  resected
tumours .
The number of  pathological ly  examined axi l lary nodes has been associated wi th
breast  cancer surv iva l  and examinat ion of  >10 nodes has been advocated for
re l iab le ax i l lary s taging.  In  chapter  3 the var iat ion in  the number of  repor ted
axi l lary lymph nodes and i ts  ef fect  on the ax i l lary nodal  s tage were studied in
4,715 pat ients d iagnosed between 1994-1997.  The number of  repor ted nodes
var ied between pathology laborator ies,  the median number of  nodes ranged
from 9 to 15 and between the indiv idual  hospi ta ls .  A decrease in the number of
examined nodes was observed in o lder  pat ients.  A h igher  number of  repor ted
nodes was associated wi th a markedly increased chance of  f ind ing tumor posi -
t ive nodes,  especia l ly  more than 3 nodes.  The f requency of  node posi t iv i ty
increased f rom 28o/o i f  less than 6 nodes were examined to 54% i f  >20 nodes
were examined,  the percentage of  tumors wi th )4 posi t ive nodes increased
from 4o/o to 31 %.
The observed regional  var iat ion in  ax i l lary s taging prompted a populat ion-
based study of  the prognost ic  impact  of  a var iable number of  examined nodes,
presented in chapter  4.  Because age was previously  found to be associated wi th
the number of  nodes examined,  the prognost ic  ef fect  of  the number of  nodes
examined was a lso assessed using re lat ive surv iva l  analys is .  The crude surv iva l
was very s imi lar  for  the ent i re pat ient  populat ion when compar ing pat ients
t d u
wi th  < ' f  0  and  >10  examined  nodes  (81 .5% ve rsus  81  .7%) .  Bu t  when  ana l ys i s  was
performed wi th s t rat i f icat ion for  the number of  posi t ive nodes,  crude surv iva l
was worse for  pat ients wi th <10 examined nodes.  When compar ing the re lat ive
surv iva l  of  pat ients wi th <10 and 210 examined nodes,  adjust ing for  var ious
pat ient  and tumor character is t ics,  the re lat ive surv iva l  was not  found to d i f fer .
The prognost ic  ef fect  of  examining more lymph nodes appeared to largely
ref lect  s tage migrat ion.  The improved staging accuracy wi l l  resul t  in  a bet ter
prognosis in  a l l  pat ient  s t rata,  as def ined in th is  s tudy by the number of  posi t ive
nodes,  but  wi l l  not  af fect  the prognosis of  the pat ient  populat ion as a whole.  As
we did not  f ind an associat ion between fewer pathological ly  examined nodes
and re lat ive surv iva l ,  the associat ion between fewer examined nodes and worse
crude surv iva l ,  observed in prev ious studies.  can probably par t ly  be expla ined by
examinat ion of  fewer lymph nodes in the e lder ly  pat ients.  When evaluat ing d is-
ease outcome in e lder ly  pat ients,  compet ing causes of  death should be account-
ed for ,  to  prevent  spur ious associat ions of  tumor character is t ics wi th surv iva l .  On
the other  hand,  the d i f ferences in  re lat ive surv iva l  associated wi th the number
of  nodes examined may have been too smal l  to  detect  in  our  populat ion.  How-
ever ,  these d i f ferences are then l ike ly  very smal l .  Another  explanat ion for  the
absence of  an associat ion between re lat ive surv iva l  and the number of  exam-
ined nodes may be the re lat ive ly  shor t  fo l low-up in our  s tudy (median 5.6 years) .
I t  is  possib le that  breast  cancer deaths at t r ibutable to understaging pat ients,
who were le f t  wrongfu l ly  untreated,  wi l l  become mani fest  only  af ter  longer fo l -
low-up.
In chapter  5 we evaluated the adminis t rat ion of  the 6 cyc le CMF regimen among
251 consecut ive ax i l lary lymph node posi t ive breast  cancer pat ients <50 years,
d iagnosed between 1993 and 1996.  The qual i ty  of  CMF was measured using the
interval  between surgery and chemotherapy,  the durat ion and dose of  CMF
chemotherapy and the resul t ing re lat ive dose intensi ty  (RDl)  of  CMF as indica-
tors.  The RDI was calculated as fo l lows.  Dose intensi ty  was calculated by summa-
r iz ing the adminis tered dose of  each drug over  the number of  courses (maxi-
mum 12 courses)  and d iv id ing th is  f igure by the pro jected tota l  dose of  each
drug over  th is  number of  courses,  mul t ip ly ing by the number of  adminis tered
cycles and d iv id ing by s ix  ( the pro jected number of  cyc les) .  The RDI fo l lows f rom
mult ip ly ing the ar i thmet ica l  mean of  the dose intensi t ies for  the three drugs
wi th the rat io  of  the pro jected number of  days for  complet ion of  the adminis-
tered number of  courses over  the actual  per iod of  t reatment .  We found that
only 94 pat ients (42%) completed adjuvant  CMF wi thout  dose adjustment  or
delay.  However;  the overal l  median RDI was 92.6 ( ln ter  Quart i le  Range 85.5-
97.7)  and 60 pat ients Qa%) had a RDI <85.  Myelotox ic i ty  was the main reason
for  reduct ions and delays.  Of  176 i r radiated pat ients,  96% received radiothera-
py s imul taneously wi th CMF. Median CMF dose intensi ty  nor  median durat ion
differed between patients who underwent mastectomy, mastectomy and radio-
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therapy,  or  breast  conserv ing therapy.  Radiotherapy d id not  in f luence the medi-
an RDl .  We concluded that  the adherence to CMF t reatment  guidel ines was gen-
era l ly  good.  Fur ther ;  s imul taneous radiotherapy d id not  af fect  the RDI of  CMF.
ln chapter  6 we assessed the r isk of  secondary invasive non-breast  cancers in  a
recently treated population-based cohort of 42,563 breast cancer patients,
focusing on the possib le associat ion wi th breast  cancer t reatment  and the prog-
nost ic  impl icat ions of  secondary non-breast  cancers.  The cohort  exper ienced
1.24- fo ld more secondary cancers than expected based on cancer inc idence rates
in the Dutch female populat ion,  or  a lmost  I  5  ext ra cancers among 1,000 women
each fo l lowed for  10 years.  Cancers of  the esophagus,  co lon,  uterus,  ovary,  k id-
ney,  sof t - t issue sarcomas,  melanomas and acute myelo id leukemia a l l  occurred
more f requent ly  than expected.  Str ik ingly ,  there was a decreased r isk of  second-
ary non-breast  cancers af ter  chemotherapy when a l l  s i tes were combined.  Acute
myelo id leukemia r isk was border l ine s igni f icant ly  increased (Hazard Rate 2.69;
95% Conf idence Interval  0.99-7.26) .  Hormonal  therapy increased endometr ia l
cancer  r isk 1.9 fo ld among pat ients >50 years.  The r isk of  sof t  t issue sarcomas
was border l ine s igni f icant ly  increased af ter  radiotherapy (Hazard Rate 2.56,
95% Conf idence Interval  0.98-6.65) .  The occurrence of  secondary non-breast
cancers d id markedly worsen the pat ient 's  prognosis (Hazard Rate 3.76,  95%
Conf idence Interval  3.53-4.01) .  We concluded that  our  resul ts ,  cover ing a 10-
year  fo l low-up per iod,  d id not  ind icate that  the issue of  t reatment- induced sec-
ondary non-breast  cancers has important  impl icat ions for  contemporary t reat-
ment  s t rategies,  s ince for  most  secondary non-breast  cancers the associat ion
wi th prev ious t reatment ,  i f  present  at  a l l ,  was weak.  The resul ts  of  a s tudy on
the impact  of  age and adjuvant  therapy on contra latera l  invasive breast  cancer
r isk and the prognost ic  s igni f icance of  contra latera l  breast  cancer are descr ibed
in chapter  7.  The study inc luded 33,930 surg ical ly  t reated stage l - l l lA breast  can-
cer  pat ients d iagnosed in the Nether lands between 1988-2000.  A tota l  o f  476
contra latera l  cancers were d iagnosed <6 months (synchronous)  and 999 >6
months (metachronous)  af ter  the index cancer.  Older  age and lobular  h is to logy
were found associated wi th an increased r isk of  synchronous contra latera l  can-
cer .  The Standardized Inc idence Rat io,  the observed number of  contra latera l
cancers divided by the number of breast cancers expected if these patients
would have had the same inc idence as the general  Dutch female populat ion,
decreased wi th age for  metachronous contra latera l  cancer .  The Standardized
lnc idence Rat io was13.4 (95% Conf idence Interval  9.6-18.2)  for  women aged
<35 and 1.6 (95o/o Conf idence Interval  1.4-1.8)  for  women aged >60 years.  The
cohort  exper ienced a lmost  30 extra cancers among 1000 women, each fo l lowed
for  10 years,  pat ients <35 years even exper ienced more than 70 extra cancers
among 1000 women, each fo l lowed for  10 years.  The cumulat ive r isk of
metachronous contra latera l  breast  cancer increased wi th about  0.5% per year ,
reaching 5.3% af ter  10 years.  A Cox Proport ional  Hazards analys is  showed that
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adjuvant  hormonal  therapy (Hazard Rat io 0.54;  95% Conf idence Interval  0.44-
0.68)  and chemotherapy (Hazard Rat io 0.67;  95% Conf idence Interval  0.51-0.87)
considerably decreased the r isk of  metachronous contra latera l  cancer .  The ef fect
of  radiotherapy d i f fered markedly according to age at  d iagnosis of  the index
cancer.  Whereas no excess r isk of  metachronous contra latera l  cancer  was seen
among pat ient  aged >40 years,  among pat ients <40 years radiotherapy was
associated wi th a 1.6- fo ld (95% Conf idence Interval  1.01-2.53)  increased r isk.
The surv iva l  of  oat ients wi th metachronous contra latera l  breast  cancer was
worse than for  uni la tera l  breast  cancer pat ients.  This s tudy showed that  young
breast  cancer pat ients exper ience a very h igh r isk of  synchronous and metachro-
nous contra latera l  cancer  and that  adjuvant  hormonal  as wel l  as chemotherapy
considerably reduced the r isk of  contra latera l  cancer .  As no decrease in r isk over
t ime was observed and metachronous contra latera l  breast  cancer negat ive ly
af fects the pat ient 's  prognosis,  long- term screening of  the contra latera l  breast
at  regular  in tervals  remains necessary.
The study presented in chapter  8 assessed the associat ion of  breast  cancer r isk
and putat ive genes wi th in the HLA region.  Using germl ine DNA, the HLA region
of  956 breast  cancer pat ients and 1,271 fami ly-based contro ls  was genotyped
wi th 24 microsate l l i te  markers and markers for  two Single Nucleot ide Polymor-
phisms (SNPs) in  TNFalpha and TNFbeta.  Wi th associat ion analyses and the hap-
lotype shar ing stat is t ic  we evaluated the HLA region for  d i f ferences in  haplo-
type shar ing between pat ients and contro ls .  The haplotype shar ing stat is t ic
showed a s igni f  icant  d i f ference between pat ients and contro ls  for  four  consecu-
tive markers (D652671, TNFa, D6526-12 and MICA), the highest being at D652671
(p = 0.017) .  For  subgroup analys is ,  pat ients were d iv ided,  based on ( fami l ia l )
breast  cancer r isk prof i le ,  in to a h igh,  moderate and low r isk group.  Intermedi-
ate r isk pat ients were pat ients wi th e i ther  b i la tera l  breast  cancer,  breast  cancer
before age 45,  or  two re lat ives wi th breast  cancers,  at  least  one of  which had
her breast  cancer d iagnosed before age 60.  High r isk pat ients fu l f i l led any of  the
moderate r isk cr i ter ia  and had a posi t ive fami ly  h is tory of  ovar ian cancer or  male
breast  cance1 had breast  cancer before age 35 or  two re lat ive wi th breast  can-
cers,  at  least  one of  which had breast  cancer d iagnosed before age 45 and the
other  before age 60.  The subgroup analyses howed that  moderate-r isk pat ients
were responsib le for  the d i f ference in mean haplotype shar ing,  wi th the
strongest association for D652672 (p = 0.0009). A single haplotype was more fre-
quent  in  moderate-r isk pat ients than in contro ls .  The resul ts  were conf i rmed
wi th associat ion analyses.  Indiv iduals homozygous for  haplotype 1 10- '184
(D652672-MICA) were observed in 9.0% of moderate-risk patients and 1 .5o/o of
contro ls  [odds rat io  (OR)=7.14] ,  whi le  heterozygotes were at  a lower r isk
(OR=1.41) ,  suggest ing a recessive f fect .  The resul ts  revealed a potent ia l  ro le of
the HLA c lass l l l  sub region in  suscept ib i l i ty  to  breast  cancer in  pat ients at  mod-
e ra te  f am i l i a l  r i s k .
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